ArticleBlood cancer journal2018
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.
Article in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple Myeloma.JCO precision oncology · 2021Trial
- Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy.Blood cancer journal · 2025Article
- Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study).Frontiers in oncology · 2025Article
- Genomic Classification and Individualized Prognosis in Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Review
- Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective.Journal of patient experience · 2023Article
- Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.Current oncology (Toronto, Ont.) · 2022Article
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.American journal of hematology · 2022Article
- Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance.Deutsches Arzteblatt international · 2022Review
- Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials.Blood advances · 2022Article
- Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.Transplantation and cellular therapy · 2022Article
- Front-line treatment patterns in multiple myeloma: An analysis of U.S.-based electronic health records from 2011 to 2019.Cancer medicine · 2021Article
- Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities.Scientific reports · 2021Article
- Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents.Bone marrow transplantation · 2021Article
- Interrupted Identities: Autologous Stem Cell Transplant in Patients With Multiple Myeloma.Journal of patient experience · 2021Article
- Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry.International journal of hematology · 2020Article
- Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and managementAmerican journal of hematology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 2 institutions in 1 country.
Funding
Abstract
Overall survival (OS) of multiple myeloma has improved remarkably over time, with the recent Intergroupe Francophone du Myelome (IFM) 2009 randomized trial reporting a 4-year OS rate of approximately 82% in patients receiving modern therapy. However, survival estimates from clinical trials may overestimate outcomes seen in clinical practice even with the adjustment for age and other key characteristics. The purpose of this study was to determine the OS of myeloma patients seen in routine clinical practice who resembled the cohort studied in the IFM 2009 trial. A second goal was to conduct a brief comparative effectiveness analysis of bortezomib, lenalidomide, dexamethasone, and other major induction regimens used during the study period. We studied all patients with myeloma 65 years of age and younger, seen at the Mayo Clinic between January 1, 2010 and August 31, 2015, who had a stem cell harvest performed within 12 months of initial diagnosis. Patients with baseline serum creatinine >2 mg/dL were excluded. Five hundred and eighteen patients were studied. The 4-year OS rate was 82.3%, comparable to results achieved in the contemporaneous IFM randomized trial. The 4-year OS rates for standard and high-risk myeloma were 86.3% and 68.2%, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.